Citations

1. (1995). A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev.
2. BMP signals inhibit proliferation and in vivo tumor growth of androgeninsensitive prostate carcinoma cells.
3. BMP-7 counteracts TGFbeta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury.
4. (1995). BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. Genes Dev.
5. (2003). BMP7 antagonizes TGF-beta-dependent fibrogenesis in mesangial cells.
6. (2005). BMP7 signaling in renal development and disease. Trends Mol Med.
7. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo.
8. (2007). BMPinduced growth suppression in colon cancer cells is mediated by p21(WAF1) stabilization and modulated by RAS/ERK. Cell Signal.
9. Bone morphogenetic protein 7 (BMP7) expression is a potential novel prognostic marker for recurrence in patients with primary melanoma.
10. (2008). Bone morphogenetic protein 7 expression associates with bone metastasis in breast carcinomas. Ann Oncol.
11. (2006). Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer. Genes Chromosomes Cancer.
12. (2005). Bone morphogenetic proteins in development and homeostasis of kidney. Cytokine Growth Factor Rev.
13. Clinical relevance of Fas expression in oesophageal squamous cell carcinoma.
14. Clinical significance of BMP7 in human colorectal cancer. Ann Surg Oncol.
15. Endothelial-tomesenchymal transition contributes to cardiac fibrosis.
16. (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer.
17. Expression of BMP-7 in human gastric cancer and its clinical significance.
18. Expression of bone morphogenetic protein-7 (BMp-7) in human prostate.
19. Expression of bone morphogenetic proteins, the subfamily of the transforming growth factorb superfamily, in renal cell carcinoma.
20. Expression of osteopontin in oesophageal squamous cell carcinoma.
21. Fleming ID. TNM classification of malignant tumors.
22. (1996). Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7).
23. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy.
24. (1995). Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer.
25. Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma.
26. Prognostic significance of CD151 expression in esophageal squamous cell carcinoma with aggressive cell proliferation and invasiveness. Ann Surg Oncol.
27. Prognostic value of cyclin B1 in patients with esophageal squamous cell carcinoma.
28. Sculpting a fly leg: BMP boundaries and cell death.
29. (2005). Signal transduction by the TGF-beta superfamily.
30. Smad4 and transforming growth factor b1 expression in patients with squamous cell carcinoma of the esophagus. Clin Cancer Res.
31. (1999). TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells.
32. The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter.
33. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.